Sanjiv Harpavat1, Joseph A Garcia-Prats2, Carlos Anaya3, Mary L Brandt4, Philip J Lupo5, Milton J Finegold6, Alice Obuobi2, Adel A ElHennawy2, William S Jarriel7, Benjamin L Shneider1. 1. Division of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston. 2. Division of Neonatology, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston. 3. University of Texas Rio Grande Valley School of Medicine and Doctors Hospital at Renaissance, Edinburg. 4. Department of Surgery, Baylor College of Medicine and Texas Children's Hospital, Houston. 5. Division of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston. 6. Department of Pathology, Baylor College of Medicine, Houston, Texas. 7. Woman's Hospital of Texas, Houston.
Abstract
Importance: Treating biliary atresia in newborns earlier can delay or prevent the need for liver transplant; however, treatment typically occurs later because biliary atresia is difficult to detect during its early stages. Objective: To determine the diagnostic yield of newborn screening for biliary atresia with direct or conjugated bilirubin measurements and to evaluate the association of screening implementation with clinical outcomes. Design, Setting, and Participants: A cross-sectional screening study of 124 385 infants born at 14 Texas hospitals between January 2015 and June 2018; and a pre-post study of 43 infants who underwent the Kasai portoenterostomy as treatment for biliary atresia at the region's largest pediatric hepatology center before (January 2008-June 2011) or after (January 2015-June 2018) screening implementation. Final follow-up occurred on July 15, 2019. Exposures: Two-stage screening with direct or conjugated bilirubin measurements. In stage 1, all newborns were tested within the first 60 hours of life, with a positive screening result defined as bilirubin levels exceeding derived 95th percentile reference intervals. In stage 2, infants who had a positive screening result in stage 1 were retested at or before the 2-week well-child visit, with a positive screening result defined as bilirubin levels greater than the stage 1 result or greater than 1 mg/dL. Main Outcomes and Measures: The primary outcomes of the screening study were sensitivity, specificity, positive predictive value, and negative predictive value based on infants testing positive in both stages. The reference standard was biliary atresia diagnosed at the region's pediatric hepatology centers. The primary outcome of the pre-post study was the age infants underwent the Kasai portoenterostomy for treatment of biliary atresia. Results: Of 124 385 newborns in the screening study, 49.2% were female, 87.6% were of term gestational age, 70.0% were white, and 48.1% were Hispanic. Screening identified the 7 known infants with biliary atresia with a sensitivity of 100% (95% CI, 56.1%-100.0%), a specificity of 99.9% (95% CI, 99.9%-99.9%), a positive predictive value of 5.9% (95% CI, 2.6%-12.2%), and a negative predictive value of 100.0% (95% CI, 100.0%-100.0%). In the pre-post study, 24 infants were treated before screening implementation and 19 infants were treated after screening implementation (including 6 of 7 from the screening study, 7 from screening at nonstudy hospitals, and 6 from referrals because of clinical symptoms). The age infants underwent the Kasai portoenterostomy was significantly younger after screening was implemented (mean age, 56 days [SD, 19 days] before screening implementation vs 36 days [SD, 22 days] after screening implementation; between-group difference, 19 days [95% CI, 7-32 days]; P = .004). Conclusions and Relevance: Newborn screening with direct or conjugated bilirubin measurements detected all known infants with biliary atresia in the study population, although the 95% CI around the sensitivity estimate was wide and the study design did not ensure complete ascertainment of false-negative results. Research is needed in larger populations to obtain more precise estimates of diagnostic yield and to better understand the clinical outcomes and cost-effectiveness of this screening approach.
Importance: Treating biliary atresia in newborns earlier can delay or prevent the need for liver transplant; however, treatment typically occurs later because biliary atresia is difficult to detect during its early stages. Objective: To determine the diagnostic yield of newborn screening for biliary atresia with direct or conjugated bilirubin measurements and to evaluate the association of screening implementation with clinical outcomes. Design, Setting, and Participants: A cross-sectional screening study of 124 385 infants born at 14 Texas hospitals between January 2015 and June 2018; and a pre-post study of 43 infants who underwent the Kasai portoenterostomy as treatment for biliary atresia at the region's largest pediatric hepatology center before (January 2008-June 2011) or after (January 2015-June 2018) screening implementation. Final follow-up occurred on July 15, 2019. Exposures: Two-stage screening with direct or conjugated bilirubin measurements. In stage 1, all newborns were tested within the first 60 hours of life, with a positive screening result defined as bilirubin levels exceeding derived 95th percentile reference intervals. In stage 2, infants who had a positive screening result in stage 1 were retested at or before the 2-week well-child visit, with a positive screening result defined as bilirubin levels greater than the stage 1 result or greater than 1 mg/dL. Main Outcomes and Measures: The primary outcomes of the screening study were sensitivity, specificity, positive predictive value, and negative predictive value based on infants testing positive in both stages. The reference standard was biliary atresia diagnosed at the region's pediatric hepatology centers. The primary outcome of the pre-post study was the age infants underwent the Kasai portoenterostomy for treatment of biliary atresia. Results: Of 124 385 newborns in the screening study, 49.2% were female, 87.6% were of term gestational age, 70.0% were white, and 48.1% were Hispanic. Screening identified the 7 known infants with biliary atresia with a sensitivity of 100% (95% CI, 56.1%-100.0%), a specificity of 99.9% (95% CI, 99.9%-99.9%), a positive predictive value of 5.9% (95% CI, 2.6%-12.2%), and a negative predictive value of 100.0% (95% CI, 100.0%-100.0%). In the pre-post study, 24 infants were treated before screening implementation and 19 infants were treated after screening implementation (including 6 of 7 from the screening study, 7 from screening at nonstudy hospitals, and 6 from referrals because of clinical symptoms). The age infants underwent the Kasai portoenterostomy was significantly younger after screening was implemented (mean age, 56 days [SD, 19 days] before screening implementation vs 36 days [SD, 22 days] after screening implementation; between-group difference, 19 days [95% CI, 7-32 days]; P = .004). Conclusions and Relevance: Newborn screening with direct or conjugated bilirubin measurements detected all known infants with biliary atresia in the study population, although the 95% CI around the sensitivity estimate was wide and the study design did not ensure complete ascertainment of false-negative results. Research is needed in larger populations to obtain more precise estimates of diagnostic yield and to better understand the clinical outcomes and cost-effectiveness of this screening approach.
Authors: Benjamin L Shneider; Morton B Brown; Barbara Haber; Peter F Whitington; Kathleen Schwarz; Robert Squires; Jorge Bezerra; Ross Shepherd; Philip Rosenthal; Jay H Hoofnagle; Ronald J Sokol Journal: J Pediatr Date: 2006-04 Impact factor: 4.406
Authors: Benjamin L Shneider; John C Magee; Saul J Karpen; Elizabeth B Rand; Michael R Narkewicz; Lee M Bass; Kathleen Schwarz; Peter F Whitington; Jorge A Bezerra; Nanda Kerkar; Barbara Haber; Philip Rosenthal; Yumirle P Turmelle; Jean P Molleston; Karen F Murray; Vicky L Ng; Kasper S Wang; Rene Romero; Robert H Squires; Ronen Arnon; Averell H Sherker; Jeffrey Moore; Wen Ye; Ronald J Sokol Journal: J Pediatr Date: 2015-12-24 Impact factor: 4.406
Authors: Jorge A Bezerra; Cathie Spino; John C Magee; Benjamin L Shneider; Philip Rosenthal; Kasper S Wang; Jessi Erlichman; Barbara Haber; Paula M Hertel; Saul J Karpen; Nanda Kerkar; Kathleen M Loomes; Jean P Molleston; Karen F Murray; Rene Romero; Kathleen B Schwarz; Ross Shepherd; Frederick J Suchy; Yumirle P Turmelle; Peter F Whitington; Jeffrey Moore; Averell H Sherker; Patricia R Robuck; Ronald J Sokol Journal: JAMA Date: 2014-05-07 Impact factor: 56.272
Authors: Richard A Schreiber; Collin C Barker; Eve A Roberts; Steven R Martin; Fernando Alvarez; Lesley Smith; J Decker Butzner; Iwona Wrobel; David Mack; Stanley Moroz; Mohsin Rashid; Rabin Persad; Dominique Levesque; Herbert Brill; Garth Bruce; Jeff Critch Journal: J Pediatr Date: 2007-10-22 Impact factor: 4.406
Authors: Lorraine I Kelley-Quon; Eveline Shue; Rita V Burke; Caitlin Smith; Karen Kling; Elaa Mahdi; Shadassa Ourshalimian; Michael Fenlon; Matthew Dellinger; Stephen B Shew; Justin Lee; Benjamin Padilla; Thomas Inge; Jonathan Roach; Ahmed I Marwan; Katie W Russell; Romeo Ignacio; Elizabeth Fialkowski; Amar Nijagal; Cecilia Im; Kenneth S Azarow; Daniel J Ostlie; Kasper Wang Journal: Pediatr Surg Int Date: 2021-12-02 Impact factor: 1.827